Division of Ultrasound, Liaocheng People’s Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng, Shandong, 252000, P. R. China
[2] Bhatti M. A.K., Ferrante J.W., Gielchinsky I., Norman J.C. Giant lymph node hyperplasia of the mediastinum (castleman’s disease): case report and review. Tex Heart Inst J., 1984, 11: 378–384
[3] Kim J. H., Jun T.G., Sung S.W., Shim Y.S., Han S.K., Kim Y.W., Yoo C.G., Seo J.W., Rho J.R. Giant lymph node hyperplasia (Castleman’s disease) in the chest. Ann Thorac Surg., 1995, 59: 1162–1165 http://dx.doi.org/10.1016/0003-4975(95)00068-V[Crossref]
[4] Seirafi P. A., Ferguson E., Edwards F.H. Thoracoscopic resection of Castleman disease: case report and review. Chest., 2003, v123:280–282 http://dx.doi.org/10.1378/chest.123.1.280[Crossref]
[5] Bandera B., Ainsworth C., Shikle J., Rupard E., Roach M. Treatment of unicentric castleman disease with neoadjuvant rituximab. Chest., 2010, 138: 1239–1241 http://dx.doi.org/10.1378/chest.09-2084[WoS][Crossref]
[7] Weisenburger D. D., Nathwani B.N., Winberg C.D., Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol., 1985,16:162–172 http://dx.doi.org/10.1016/S0046-8177(85)80065-4[Crossref]
[8] Slotwiner A., Garwacki C.P., Moll S. Castleman’s disease. Am J Hematol., 2003,73:64–65 http://dx.doi.org/10.1002/ajh.10318[Crossref]
[9] McAdams H. P., Rosado-de-Christenson M.R., Fishback N.F., Templeton P.A. Castleman disease Of the thorax: radiologic features with clinical and histopatholigic correlation. Radiology., 1998, 209, 221–228
[10] Kim M. H., Hwang S., Choi Y.B., Oh S.T., Kim S.C., Choi G.M., Ahn C.S., Kim K.H., Moon D.B., Ha T.Y., Song G.W., Jung D.H., Yu E.S., Lee S.G. Castleman disease of the abdomen-single-center experience of 13 surgically treated patients over 11 years. Hepato-Gastroenterol., 2010, 57, 1060–1063
[11] Dispenzieri A., Gertz M.A. Treatment of Castleman’s disease. Curr Treat Options Oncol., 2005, 6, 255–266 http://dx.doi.org/10.1007/s11864-005-0008-z[Crossref]
[12] Chronowski G. M., Ha C.S., Wilder R.B., Cabanillas F., Manning J., Cox J.M. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001, 92, 670. http://dx.doi.org/10.1002/1097-0142(20010801)92:3<670::AID-CNCR1369>3.0.CO;2-Q[Crossref]
[13] Powles T., Stebbing J., Bazeos A., Hatzimichael, E., Mandalia, S., Nelson, M., Gazzard, B., Bower, M. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol., 2009, 20, 775–779 http://dx.doi.org/10.1093/annonc/mdn697[WoS][Crossref]
[14] van Rhee F., Fayad L., Voorhees P., Furman R., Lonial S., Borghaei H., Sokol L., Crawford J., Cornfeld M., Qi M., Qin X., Herring J., Casper C., Kurzrock R. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol., 2010, 28, 3701–3708 http://dx.doi.org/10.1200/JCO.2009.27.2377[Crossref][WoS]